Apalutamide Maintains Health-Related QoL in Nonmetastatic CRPC
Fred Saad, MD, discusses the clinical significance of the SPARTAN trial, the HRQoL data, and remaining steps in the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Source: OncLive